ZYUS Life Sciences Corporation (ZYUS) - Total Liabilities
Based on the latest financial reports, ZYUS Life Sciences Corporation (ZYUS) has total liabilities worth CA$23.82 Million CAD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ZYUS Life Sciences Corporation - Total Liabilities Trend (2022–2024)
This chart illustrates how ZYUS Life Sciences Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ZYUS Life Sciences Corporation Competitors by Total Liabilities
The table below lists competitors of ZYUS Life Sciences Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jentayu Sustainables Bhd
KLSE:5673
|
Malaysia | RM63.70 Million |
|
Phenom Resources Corp
V:PHNM
|
Canada | CA$180.24K |
|
SHL Telemedicine Ltd American Depositary Shares
NASDAQ:SHLT
|
USA | $41.51 Million |
|
Beauty Community Public Company Limited
BK:BEAUTY
|
Thailand | ฿81.31 Million |
|
Aurora Mobile Ltd
NASDAQ:JG
|
USA | $316.94 Million |
|
Wellbiotec Co. Ltd.
KO:010600
|
Korea | ₩11.76 Billion |
|
Singbao International Co Ltd
TWO:6130
|
Taiwan | NT$231.12 Million |
|
Wintec Co. Ltd
KQ:320000
|
Korea | ₩14.21 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down ZYUS Life Sciences Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ZYUS Life Sciences Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ZYUS Life Sciences Corporation (2022–2024)
The table below shows the annual total liabilities of ZYUS Life Sciences Corporation from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$20.02 Million | +8.12% |
| 2023-12-31 | CA$18.51 Million | -69.13% |
| 2022-12-31 | CA$59.97 Million | -- |
About ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries,… Read more